Targets › CRHR1
4 programs from 4 companies in 6 trials: 4 Phase 2, 2 Phase 3; Respiratory, Genitourinary; next expected readout Dec 2026.
G protein-coupled receptor for CRH and UCN stress hormones, which plays a central role in whole body adaptation to stress. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and downstream effectors, such as adenylate cyclase. (UniProt, P34998)
Open in Phaseline: the race on CRHR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Neurocrine Biosciences | Crinecerfont Corticotropin releasing factor receptor 1 antagonist | CRHR1 | Phase 3 | Congenital Adrenal Hyperplasia | Aug 2027 |
| Shionogi | Sivopixant CRF1 receptor antagonist | CRHR1 | Phase 2 | Sleep Apnea | Dec 2026 |
| Chiesi Farmaceutici | CHF5993 pMDI 100/6/12.5 µg with HFA-152a Triple combination: inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA), long- | ADRB2, CRHR1 | Phase 2 | Asthma | Jun 2027 |
| Neurocrine Switzerland | Crinecerfont Corticotropin releasing factor receptor 1 antagonist | CRHR1 | Phase 2 | Congenital Adrenal Hyperplasia | Mar 2028 |
Congenital Adrenal Hyperplasia (4) Asthma (1) Sleep Apnea (1)
small molecule (4)
Chiesi Farmaceutici (1) Neurocrine Switzerland (1) Shionogi (1) Neurocrine Biosciences (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.